Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02514499 · ClinicalTrials.gov registry record · NA
Multiplex Testing for Evaluation of Breast Cancer Risk, Longitudinal Study
A NA study of BRCA1/2 Negative, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- NA
- Development phase
- 350
- Enrollment target
- 1
- Study location
NCT02514499: Completed NA study of BRCA1/2 Negative, sponsored by Abramson Cancer Center at Penn Medicine.
NCT02514499 is a NA study of BRCA1/2 Negative that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 350 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02514499, a NA study of BRCA1/2 Negative, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 350 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall goal of the proposed research is to evaluate the uptake of testing and longitudinal risks and benefits of multiplex testing for cancer susceptibility in BRCA1/2 negative patients. This model will inform the selection of the outcomes and potential mediators and moderators of these outcomes, to inform the debate over utility, risks, and benefits of clinical incorporation of multiplex testing for breast cancer susceptibility.
Conditions Studied
Interventions
- OTHER Questionnaires
Study Locations (1)
Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2014-07 |
| Est. Completion | 2018-10 |
| Phase | NA |
What the finished NCT02514499 record still lists
NCT02514499 is an interventional study that assigns participants to a tested intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (75% lower).
The record links to 1 condition, with BRCA1/2 Negative appearing as the primary indexed condition, and to 1 intervention - of which Questionnaires is the first listed.
NCT02514499 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02514499 about?
NCT02514499 is a clinical study titled "Multiplex Testing for Evaluation of Breast Cancer Risk, Longitudinal Study". The overall goal of the proposed research is to evaluate the uptake of testing and longitudinal risks and benefits of multiplex testing for cancer susceptibility in BRCA1/2 negative patients. This model will inform the selection of the outcomes and potential mediators and moderators of these outcome...
What is the current status of trial NCT02514499?
This trial is currently completed. It is a NA study. The enrollment target is 350 participants. The study started on 2014-07. Estimated completion is 2018-10.
What conditions does trial NCT02514499 study?
This clinical trial studies the following conditions: BRCA1/2 Negative.
What interventions are being tested in trial NCT02514499?
The interventions under investigation include: Questionnaires (OTHER).
Who is sponsoring clinical trial NCT02514499?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02514499 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02514499's enrollment target sits among peer trials
350 292nd of 2000 higher than 1,699 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900575 · 350 participants · NA
Cervical Cancer Detection Using Optical Spectroscopy
- NCT01627821 · 350 participants · NA
Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study
- NCT02357654 · 350 participants · Phase 4
GnRH for Luteal Support in IVF/ICSI/FET Cycles
- NCT03997370 · 350 participants · Phase 1
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia